Charles Riv­er bags a ri­val CRO play­er in $800M MPI Re­search buy­out

The on­go­ing con­sol­i­da­tion of the CRO busi­ness is con­tin­u­ing this morn­ing as Charles Riv­er Lab­o­ra­to­ries $CRL wraps up an $800 mil­lion cash deal to ac­quire MPI Re­search, one of its biggest com­peti­tors in the pre­clin­i­cal sphere.

The ear­ly-stage spe­cial­ists at Charles Riv­er saw a sweet line­up of dis­cov­ery ser­vices at the 25-year-old MPI that fits with its own mis­sion in the in­dus­try.

Charles Riv­er is a buy­er in the CRO world. Just weeks ago it ac­quired KWS BioTest and its in vi­vo and in vit­ro dis­cov­ery ser­vices for £15 mil­lion (rough­ly $20 mil­lion) up front. And it’s been wrack­ing up a long string of ac­qui­si­tions over the past few years as top play­ers con­tin­ue to carve out mar­ket share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER